{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:42:51Z","timestamp":1740181371729,"version":"3.37.3"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014088","name":"AstraZeneca SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.resmer.2024.101113","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T19:20:53Z","timestamp":1714504853000},"page":"101113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-8610","authenticated-orcid":false,"given":"Denis","family":"Moro-Sibilot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Falchero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Ardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayoube","family":"Zouak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Molinier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Romand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Amrane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lia","family":"Berndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Langlais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resmer.2024.101113_bib0001","doi-asserted-by":"crossref","first-page":"e7835","DOI":"10.1371\/journal.pone.0007835","article-title":"Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results","volume":"4","author":"Oze","year":"2009","journal-title":"PLoS ONE"},{"issue":"Suppl 2","key":"10.1016\/j.resmer.2024.101113_bib0002","doi-asserted-by":"crossref","first-page":"ii235","DOI":"10.1093\/annonc\/mdi700","article-title":"Management of small-cell lung cancer","volume":"16","author":"Thatcher","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0003","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1200\/JCO.1994.12.10.2022","article-title":"Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer","volume":"12","author":"Ihde","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0004","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.1997.15.5.2082","article-title":"Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study","volume":"15","author":"Pujol","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0005","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/jnci\/dji114","article-title":"Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer","volume":"97","author":"Lorigan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.resmer.2024.101113_bib0006","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/93.4.300","article-title":"Etoposide plus cisplatin with or without the combination of 4\u2019-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study","volume":"93","author":"Pujol","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.resmer.2024.101113_bib0007","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1200\/JCO.2004.00.9969","volume":"23","author":"Thatcher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0008","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2024.101113_bib0009","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.resmer.2024.101113_bib0010","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0011","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/JCO.2020.38.15_suppl.9000","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"38","author":"Leal","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0013","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0014","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0015","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resmer.2024.101113_bib0016","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","article-title":"A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial","volume":"14","author":"Pujol","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0017","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.resmer.2024.101113_bib0018","first-page":"958","article-title":"Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide","volume":"49","author":"Hwang","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.resmer.2024.101113_bib0019","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/excr.1994.1265","article-title":"Role of topoisomerase II in the structural and functional evolution of mitogen-stimulated lymphocyte nuclei","volume":"214","author":"Daev","year":"1994","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.resmer.2024.101113_bib0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.cdd.4400595","article-title":"The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes","volume":"7","author":"Ferraro","year":"2000","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.resmer.2024.101113_bib0021","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2169\/internalmedicine.1001-18","article-title":"Pembrolizumab-induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in non-small cell lung cancer","volume":"58","author":"Okawa","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.resmer.2024.101113_bib0022","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated t cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.resmer.2024.101113_bib0023","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2018.11.025","article-title":"Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide","volume":"107","author":"Rios","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resmer.2024.101113_bib0024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002620000122","article-title":"The immunological effects of taxanes","volume":"49","author":"Chan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.resmer.2024.101113_bib0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0026","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1054\/bjoc.2000.1541","article-title":"Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study","volume":"84","author":"Gridelli","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.resmer.2024.101113_bib0027","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1200\/JCO.2001.19.5.1320","article-title":"Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a groupe Fran\u00e7ais de Pneumo-canc\u00e9rologie study","volume":"19","author":"Thomas","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0028","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resmer.2024.101113_bib0029","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.ejca.2007.07.029","article-title":"Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer","volume":"43","author":"de Jong","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resmer.2024.101113_bib0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.resmer.2024.101113_bib0031","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2012.06.006","article-title":"Multidisciplinary Thoracic Oncology Group. Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients","volume":"78","author":"Nagy-Mignotte","year":"2012","journal-title":"Lung Cancer"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041224000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041224000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T08:03:44Z","timestamp":1734163424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041224000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"alternative-id":["S2590041224000291"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2024.101113","relation":{},"ISSN":["2590-0412"],"issn-type":[{"type":"print","value":"2590-0412"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2024.101113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101113"}}